| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 5,175 | 19,223 | 14,745 | 26,082 |
| Cost of revenue | 14,687 | 20,161 | 21,829 | 12,079 |
| Research and development | 121,062 | 128,636 | 129,634 | 74,600 |
| General and administrative | 41,628 | 46,653 | 54,650 | 37,757 |
| Total operating costs and expenses | 177,377 | 195,450 | 206,113 | 124,436 |
| Loss from operations | -172,202 | -176,227 | -191,368 | -98,354 |
| Other income, net | 9,952 | 4,330 | -11,277 | 2,679 |
| Loss before income tax benefit | -162,250 | -171,897 | -202,645 | -95,675 |
| Income tax benefit (expense) | 3 | 0 | -158 | 167 |
| Net loss | -162,253 | -171,897 | -202,487 | -95,842 |
| Net loss per share of class a, b and exchangeable common stock, basic (in dollars per share) | -0.36 | -0.41 | -0.5 | -0.34 |
| Net loss per share of class a, b and exchangeable common stock, diluted (in dollars per share) | -0.36 | -0.41 | -0.5 | -0.34 |
| Weighted-average shares (class a, b and exchangeable) outstanding, basic (in shares) | 446,988,046 | 417,361,147 | 402,771,972 | 282,583,048 |
| Weighted-average shares (class a, b and exchangeable) outstanding, diluted (in shares) | 446,988,046 | 417,361,147 | 402,771,972 | 282,583,048 |
RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)